PixarBio (PixarBio) Total Long-Term Assets : $0.36 Mil (As of Sep. 2016)

View and export this data going back to 2016. Start your Free Trial

What is PixarBio Total Long-Term Assets?

Total Long-Term Assets includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets. PixarBio's Total Long-Term Assets for the quarter that ended in Sep. 2016 was $0.36 Mil.

PixarBio Total Long-Term Assets Historical Data

The historical data trend for PixarBio's Total Long-Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PixarBio Total Long-Term Assets Chart

PixarBio Annual Data

Trend

Dec14

Dec15

Total Long-Term Assets

0.37

0.36

PixarBio Quarterly Data
	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16
Total Long-Term Assets	Get a 7-Day Free Trial					0.37	0.36	0.36	0.36	0.36

PixarBio Total Long-Term Assets Calculation

Total Long-Term Assets are the sum of the carrying amounts of all assets that are expected to be realized in cash, sold or consumed longer than one year. It includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets.

PixarBio Total Long-Term Assets Related Terms

Thank you for viewing the detailed overview of PixarBio's Total Long-Term Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

PixarBio (PixarBio) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PixarBio Corp (GREY:PXRB) » Definitions » Total Long-Term Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

200 Boston Avenue, Suite 1875, Medford, MA, USA, 02155

Website

https://www.pixarbio.com

PixarBio Corp is a specialty pharmaceutical company focused on preclinical and clinical commercial development of therapeutic drug delivery systems for post-operative pain. The company's lead clinical candidate, NeuroRelease is a non-opioid / non-opiate preclinical stage product intended for the treatment of surgical pain, with planned future indications for chronic pain. NeuroRelease blocks nociceptive and neuropathic pain signals arising from temperature and pressure stimuli without affecting motor function, which is intended to allow for effective treatment without delaying post-surgical physical therapy.